BiomX

Customized phage therapies to eradicate harmful bacteria in chronic diseases.

Launch date

Feb 2015

Employees

Market cap

Enterprise valuation

$28m (Public information from Sep 2024)

Ness Ziona Center District (HQ)

http://www.biomx.com/

https://twitter.com/biomx_inc https://www.linkedin.com/company/biomxbio/

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
EBITDA	(27.7m)	(33.9m)	(24.7m)	(23.1m)	(36.9m)	(43.3m)	(51.0m)
Profit	(30.1m)	(36.2m)	(28.3m)	(26.2m)	(28.2m)	(35.1m)	(45.9m)
EV / EBITDA	-5.3x	-1.3x	-0.2x	-0.6x	-0.6x	-0.5x	-0.4x
R&D budget	20.9m	22.7m	16.2m	16.7m	-	-	-

Date	Investors	Amount	Round
-	Baruch Future Ventures FutuRx	N/A	-
May 2017*	Seventure Partners Mirae Asset Venture Investment Takeda Ventures OrbiMed Innovation Fund Johnson & Johnson Innovation SBI Japan-Israel Innovation Fund Takeda	€21.8m	Series A
Nov 2018	Falling Walls Venture	N/A	Support Program
Feb 2019*	Seventure Partners Mirae Asset Venture Investment Takeda Ventures OrbiMed 8VC Johnson & Johnson Innovation SBI Japan-Israel Innovation Fund RM Global - RMG Consensus Business Group KB Investment Chong Kun Dang Pharm.	$32.0m	Series B
Mar 2019	N/A	N/A	IPO
Feb 2023*	Cystic Fibrosis Foundation OrbiMed	$7.5m	Private Placement VC
Mar 2024*	Cystic Fibrosis Foundation OrbiMed Deerfield AMR Action Fund Nantahala Capital Management	$50.0m	Private Placement VC
Total Funding		$113m

Tech stackLearn more about the technologies and tools that this company uses.

Adaptive Phage Therapeutics

ACQUISITION by BiomX Mar 2024

ACQUISITION by BiomX Dec 2017